Goldstein David M 4

Accession 0001209191-20-052223

CIK 0001510487other

Filed

Sep 27, 8:00 PM ET

Accepted

Sep 28, 5:08 PM ET

Size

26.1 KB

Accession

0001209191-20-052223

Form 4

Period: 2020-09-28

Chief Scientific Officer

Transactions

Disposition from Tender
Common Stock
2020-09-28$100.00/sh−31,826$3,182,600→ 0 total
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−15,412→ 0 total
Exercise: $5.00Exp: 2025-07-20→ Common Stock (15,412 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−34,677→ 0 total
Exercise: $7.27Exp: 2027-12-13→ Common Stock (34,677 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−44,034→ 0 total
Exercise: $11.35Exp: 2028-08-23→ Common Stock (44,034 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−60,000→ 0 total
Exercise: $35.42Exp: 2029-02-28→ Common Stock (60,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−22,017→ 0 total
Exercise: $5.00Exp: 2026-03-14→ Common Stock (22,017 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−75,000→ 0 total
Exercise: $67.31Exp: 2030-03-04→ Common Stock (75,000 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−12,960→ 0 total
Exercise: $3.18Exp: 2024-06-26→ Common Stock (12,960 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−13,210→ 0 total
Exercise: $4.72Exp: 2024-12-25→ Common Stock (13,210 underlying)
Disposition to Issuer
Employee Stock Option (right to buy)
2020-09-28−8,807→ 0 total
Exercise: $4.72Exp: 2024-12-25→ Common Stock (8,807 underlying)

Footnotes (3)

[F1]Pursuant to the Agreement and Plan of Merger, dated as of August 16, 2020, by and among Principia Biopharma Inc. (the "Issuer"), Sanofi ("Sanofi") and Kortex Acquisition Corp. ("Purchaser") (the "Merger Agreement"), on September 28, 2020, Purchaser merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Sanofi (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $100.00 per share in cash, without interest and subject to any applicable withholding taxes.
[F2]Includes 87 shares acquired under the Employment Stock Purchase Plan on September 25, 2020.
[F3]Pursuant to the Merger Agreement, at the Effective Time, each of the unvested and outstanding options was accelerated and became fully vested, and each of the outstanding options was canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options, multiplied by (ii) the excess (if any) of (x) $100.00 over (y) the exercise price payable per share under such options.

Documents

1 file

Principia Biopharma Inc.

CIK 0001510487

Entity typeother